These SLU-PP-332 capsules contain the same molecule as the vial format — a small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) — in a pre-portioned capsule presentation for laboratory research workflows. Chemically it is the acylhydrazone 4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide, with formula C18H14N2O2, molecular weight 290.32 g/mol, CAS 303760-60-3, and PubChem CID 5404083. It activates all three ERR isoforms with reported EC50 values of approximately 98 nM (ERRα), 230 nM (ERRβ), and 430 nM (ERRγ).
The capsule format delivers a fixed, uniform amount of SLU-PP-332 research material per unit, which some laboratories prefer for consistency across study arms. The molecular identity, ERR target profile, and mechanism are identical to the vial form; only the physical presentation differs. Supplied strictly as research material for laboratory use — Research Use Only.
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
As the same molecule as the vial format, SLU-PP-332 has been investigated in experimental and preclinical settings as a pan-ERR agonist engaging the estrogen-related receptor family to drive oxidative-metabolism gene programs. Studies report that, in rodent models of metabolic syndrome, it increases energy expenditure and fatty acid oxidation, decreases fat mass, and improves insulin sensitivity via enhanced mitochondrial biogenesis.
Owing to overlap between ERR activation and exercise-associated transcription, SLU-PP-332 is described in the literature as an "exercise mimetic" tool compound and studied in cardiac-metabolism and endurance-adaptation contexts. The capsule format does not alter these research findings, which derive from preclinical, experimental, or in-vitro models and are provided for research context only.
SLU-PP-332 was developed at Saint Louis University School of Medicine by the laboratory of Thomas Burris as a structural optimization of the ERR agonist GSK4716, in which a naphthalene ring replaced the isopropylphenyl group to increase ERRα potency roughly 50-fold. It has since been characterized across peer-reviewed studies of metabolic syndrome, mitochondrial biogenesis, and exercise-adaptation pathways, and is offered in multiple formats including capsules.
View compound profile on NIH PubChem →
Cited literature refers to laboratory and preclinical research. SLU-PP-332 Capsules is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
